ImmunityBio (ImmunityBio) Current Accrued Expense : $23.42 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Current Accrued Expense?

ImmunityBio's Current Accrued Expense for the quarter that ended in Mar. 2024 was $23.42 Mil.

ImmunityBio's quarterly Current Accrued Expense declined from Sep. 2023 ($48.90 Mil) to Dec. 2023 ($24.40 Mil) and declined from Dec. 2023 ($24.40 Mil) to Mar. 2024 ($23.42 Mil).

ImmunityBio's annual Current Accrued Expense declined from Dec. 2021 ($34.86 Mil) to Dec. 2022 ($22.09 Mil) but then increased from Dec. 2022 ($22.09 Mil) to Dec. 2023 ($24.40 Mil).

ImmunityBio Current Accrued Expense Historical Data

The historical data trend for ImmunityBio's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Current Accrued Expense Chart

ImmunityBio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

18.78

34.86

22.09

24.40

ImmunityBio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial													33.16	37.24	48.90	24.40	23.42

ImmunityBio Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

ImmunityBio Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio (ImmunityBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

26CA:Germany

Address

3530 John Hopkins Court, San Diego, CA, USA, 92121

Website

https://www.immunitybio.com

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

Executives

Patrick Soon-shiong	director, 10 percent owner, officer: See remarks	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc	10 percent owner	10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk	director	C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark	director	C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer	officer: Chief Accounting Officer	4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock	officer: Chief Executive Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs	officer: Chief Financial Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll	director